Cadrenal Therapeutics, Inc. Files Prospectus Supplement for At-the-Market Offering

Cadrenal Therapeutics, Inc. has filed a prospectus supplement with the SEC for its at-the-market (ATM) offering program. The company intends to offer and sell up to $1,770,028 of its common stock through H.C. Wainwright & Co., LLC as the sales agent. This offering is made under an existing ATM Agreement and is pursuant to a registration statement on Form S-3. As of the filing date, the company has already sold $10,005,300 of its common stock under the ATM Agreement. The agreement allows the company to set parameters for the sale of shares, including volume and pricing, with Wainwright acting as the sales agent. Wainwright will receive a 3.0% commission on gross sales. The company has the right to suspend or terminate the agreement. Blank Rome LLP has provided a legal opinion on the validity of the shares to be offered.